MA46690A - Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 - Google Patents

Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2

Info

Publication number
MA46690A
MA46690A MA046690A MA46690A MA46690A MA 46690 A MA46690 A MA 46690A MA 046690 A MA046690 A MA 046690A MA 46690 A MA46690 A MA 46690A MA 46690 A MA46690 A MA 46690A
Authority
MA
Morocco
Prior art keywords
triazolo
pyrimidine compounds
pde2 inhibitors
pde2
inhibitors
Prior art date
Application number
MA046690A
Other languages
English (en)
Inventor
Peter Jacobus Johannes Antonius Buijnsters
Henricus Jacobus Maria Gijsen
Gary John Tresadern
Den Keybus Frans Alfons Maria Van
Roosbroeck Yves Emiel Maria Van
Adriana Ingrid Velter
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA46690A publication Critical patent/MA46690A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA046690A 2016-11-02 2017-10-31 Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 MA46690A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16196936 2016-11-02

Publications (1)

Publication Number Publication Date
MA46690A true MA46690A (fr) 2019-09-11

Family

ID=57223577

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046690A MA46690A (fr) 2016-11-02 2017-10-31 Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2

Country Status (13)

Country Link
US (1) US11319321B2 (fr)
EP (1) EP3535268B1 (fr)
JP (1) JP7018944B2 (fr)
KR (1) KR20190067788A (fr)
CN (1) CN109890824B (fr)
AU (1) AU2017353313C1 (fr)
BR (1) BR112019008604A2 (fr)
CA (1) CA3038913A1 (fr)
EA (1) EA039847B1 (fr)
ES (1) ES2912264T3 (fr)
MA (1) MA46690A (fr)
MX (1) MX390505B (fr)
WO (1) WO2018083101A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2765738T3 (es) 2015-11-02 2020-06-10 Janssen Pharmaceutica Nv Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo
EP3535269B1 (fr) * 2016-11-02 2020-12-09 Janssen Pharmaceutica NV Composés de [1,2,4]triazolo[1,5-a]pyrimidine comme inhibiteurs de pde2
KR20190067788A (ko) 2016-11-02 2019-06-17 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물
UA125302C2 (uk) 2016-11-02 2022-02-16 Янссен Фармацевтика Нв Похідні [1,2,4]триазоло[1,5-a]піримідину як інгібітори pde2
CA3045745A1 (fr) * 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Derives de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitues par de la piperidine, de la morpholine ou de la piperazine utilises en tant qu'inhibiteurs d'oga
CN115960101B (zh) * 2022-12-30 2024-10-18 海南大学 7-氧代-4,5,6,7-四氢吡唑并吡啶酰胺类化合物及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
WO1999037304A1 (fr) 1998-01-27 1999-07-29 Aventis Pharmaceuticals Products Inc. COMPOSES OXOAZAHETEROCYCLYLE SUBSTITUES INHIBITEURS DU FACTEUR Xa
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
PL376149A1 (en) 2002-10-03 2005-12-27 Vertex Pharmaceuticals Incorporated Piperazine and piperidine derivatives for treatment of neurological diseases
US20070275961A1 (en) 2003-06-04 2007-11-29 Vernalis (Cambridge) Limited. Triazolo ' 1, 5-A ! Pyrimidines and Their Use in Medicine
ES2317031T3 (es) 2003-07-16 2009-04-16 Janssen Pharmaceutica Nv Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3.
JP4707560B2 (ja) 2003-12-29 2011-06-22 Ｍｓｄ株式会社 新規２−ヘテロアリール置換ベンズイミダゾール誘導体
WO2006034341A2 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
CA2580855A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2007113136A1 (fr) 2006-03-30 2007-10-11 Basf Aktiengesellschaft Utilisation de triazolopyrimidines substituées dans la lutte contre des champignons phytopathogènes
JP2007332061A (ja) 2006-06-14 2007-12-27 Nippon Kayaku Co Ltd 新規ピラゾロ［１，５−ａ］ピリミジン誘導体及びその用途
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
US7928103B2 (en) 2006-10-17 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US8138168B1 (en) 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP2010065024A (ja) * 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
PE20140236A1 (es) 2011-02-23 2014-03-14 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
WO2013042139A1 (fr) 2011-09-23 2013-03-28 Advinus Therapeutics Limited Composés amides, compositions et applications de ceux-ci
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
CN106255679B (zh) 2014-02-27 2019-09-06 默克专利有限公司 用作nav通道抑制剂的杂环化合物及其用途
SG11201607794QA (en) 2014-03-19 2016-10-28 Boehringer Ingelheim Int Heteroaryl syk inhibitors
HUE057317T2 (hu) 2014-04-23 2022-04-28 Dart Neuroscience Llc Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok
CR20160493A (es) 2014-04-25 2016-12-16 Pfizer Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
CN105566321B (zh) 2014-10-29 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
TWI530688B (zh) 2014-11-18 2016-04-21 彭顯智 製備微奈米探針設備及方法
WO2016107602A1 (fr) 2015-01-01 2016-07-07 成都贝斯凯瑞生物科技有限公司 Dérivés hétérocycliques d'azote substitués et leur utilisation
WO2016145614A1 (fr) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Composés de triazolyl pyrimidinone en tant qu'inhibiteurs de pde2
WO2017000277A1 (fr) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclo-composés de triazole substitués utilisés en tant qu'inhibiteurs de pde2
WO2017000276A1 (fr) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Composés hétérocycliques bicycliques utilisés en tant qu'inhibiteurs de pde2
CA3001857A1 (fr) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Composes, compositions et methodes d'utilisation contre des granules de stress
ES2765738T3 (es) 2015-11-02 2020-06-10 Janssen Pharmaceutica Nv Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo
WO2017157882A1 (fr) 2016-03-14 2017-09-21 Université Catholique de Louvain Inhibiteurs de la voie de biosynthèse de la sérine
EP3535269B1 (fr) 2016-11-02 2020-12-09 Janssen Pharmaceutica NV Composés de [1,2,4]triazolo[1,5-a]pyrimidine comme inhibiteurs de pde2
KR20190067788A (ko) 2016-11-02 2019-06-17 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물
UA125302C2 (uk) 2016-11-02 2022-02-16 Янссен Фармацевтика Нв Похідні [1,2,4]триазоло[1,5-a]піримідину як інгібітори pde2
CA3044762A1 (fr) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Composes inhibiteurs d'oga bicyclique

Also Published As

Publication number Publication date
CN109890824B (zh) 2022-05-24
MX390505B (es) 2025-03-20
EP3535268A1 (fr) 2019-09-11
US20200055858A1 (en) 2020-02-20
AU2017353313C1 (en) 2022-06-09
ES2912264T3 (es) 2022-05-25
EP3535268B1 (fr) 2022-02-09
EA201991094A1 (ru) 2019-09-30
JP7018944B2 (ja) 2022-02-14
BR112019008604A2 (pt) 2019-07-09
CN109890824A (zh) 2019-06-14
KR20190067788A (ko) 2019-06-17
CA3038913A1 (fr) 2018-05-11
AU2017353313B2 (en) 2021-09-16
EA039847B1 (ru) 2022-03-18
AU2017353313A1 (en) 2019-04-18
WO2018083101A1 (fr) 2018-05-11
US11319321B2 (en) 2022-05-03
MX2019005123A (es) 2019-06-20
JP2019532990A (ja) 2019-11-14

Similar Documents

Publication Publication Date Title
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu&#39;inhibiteurs de la kinase ret
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu&#39;inhibiteurs de jak
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
MA50375A (fr) Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu&#39;inhibiteurs pde2
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
DK3322706T3 (da) Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
LT3555097T (lt) Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
EP3328840A4 (fr) Composés bicycliques triazolo substitués en tant qu&#39;inhibiteurs de pde2
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
SG11201801365YA (en) NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu&#39;inhibiteurs de pde2
ME03672B (fr) 1h-pyrazolo [4,3-b]pyridines en tant qu&#39;inhibiteurs de pde1
MA43021A (fr) Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu&#39;inhibiteurs doubles de dyrk1/clk1
EP2525659A4 (fr) Composés pyrazolo[1,5-a]pyrimidines en tant qu&#39;inhibiteurs de mtor
EP3722298A4 (fr) Dérivé de pyrrolo(pyrazolo)pyrimidine utilisé en tant qu&#39;inhibiteur de lrrk2
EP3380475A4 (fr) Dérivés d&#39;octahydropyrrolo [3, 4-c
EP3096762C0 (fr) Pyrazolo[1,5-a]pyrimidines comme composés antiviraux
EP3508487A4 (fr) COMPOSÉ DE PYRAZOLO [1,5-a]PYRIMIDINE
EP3319966A4 (fr) Composés hétérocycliques bicycliques utilisés comme inhibiteurs de pde2
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
EP3551630A4 (fr) Dérivés d&#39;imidazo [1,5-a]pyrazine en tant qu&#39;inhibiteurs de pi3kdelta
EP3679042A4 (fr) Dérivés d&#39;imidazo[1,5-a]pyrazine en tant qu&#39;inhibiteurs de pi3kdelta
EP3313852A4 (fr) Composés bicycliques pyrazolo/imidazolo substitués en tant qu&#39;inhibiteurs de pde2
MA41174A (fr) Dérivés d&#39;imidazopyridazine utilisés en tant qu&#39;inhibiteurs de pi3kbeta